Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...
Clinical Trials Arena on MSN6d
Vertex halts development of diabetes cell therapy after trial failureVertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback